免疫タンパク質診断検査の世界市場-2022-2029

市場力学

免疫タンパク質診断検査市場は、肥満、関節リウマチ、がん、2型糖尿病、感染症、心血管疾患の有病率の上昇により成長しています。

技術の進歩と肥満、関節リウマチ、癌の有病率の上昇が市場成長の原動力になると予想されます。

世界保健機関（WHO）によると、2020年までに世界の全死亡者のほぼ4分の3を慢性疾患が占め、死亡者の71％が虚血性心疾患（IHD）、75％が脳卒中、70％が糖尿病による死亡で、発展途上国で発生すると予測されています。途上国の糖尿病患者数は、1995年の8400万人から2025年には2億2800万人と2.5倍以上に増加すると言われています。世界的に見ると、慢性疾患の負担の60％が新興国で発生すると言われています。実際、心血管疾患は、現在でもインドと中国において、世界のすべての経済的先進国を合わせたよりも多く発生しています。過体重と肥満に関しては、現在の有病率がすでに前例のないレベルに達しているだけでなく、ほとんどの発展途上地域で毎年増加している割合が相当なものです。この現象が公衆衛生に及ぼす影響は甚大であり、すでに明らかになりつつあります。したがって、慢性疾患の増加により、迅速な診断に対する需要が高まっています。

老年人口の増加と慢性疾患の発生率の高さが、免疫タンパク質診断検査の世界市場の成長に拍車をかけています。さらに、免疫タンパク質診断検査に対する需要の高まりは、世界の感染症の流行にも起因していると考えられます。特に低開発地域における不衛生な生活環境も、病気や感染症を引き起こす要因となっています。このため、免疫タンパク質診断検査の世界市場は注目されています。

診断検査にかかるコストの高さが市場成長の妨げになることが予想されます。

規制の枠組みは非常に複雑で、多くの免疫タンパク質診断検査を簡単に承認することはできず、一部の診断テストのコストが高いことが市場の成長を阻害する可能性があります。

産業分析

免疫タンパク質診断検査の世界市場は、ポーターのファイブフォース、規制分析、サプライチェーン分析、価格分析、製品イノベーション、アンメットニーズなどの様々な産業要因に基づいて、市場の詳細な分析を提供します。

世界の免疫タンパク質診断検査市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 技術の進歩、肥満、関節リウマチ、癌の有病率の増加
  • 抑制要因
    • デバイスとメンテナンスの高コスト
    • 手術別怪我のリスク
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 規制分析
• サプライチェーン分析
• プライシング分析
• 製品イノベーション
• アンメットニーズ

第6章 検査タイプ別

• 免疫グロブリン診断テスト
• C反応性タンパク質（CRP）診断薬
• 補体系タンパク質診断薬
• 遊離軽鎖診断薬
• ハプトグロビン診断薬
• プレアルブミン診断薬
• その他

第7章 アプリケーション別

• 自己免疫疾患検査
• 感染症検査
• オンコロジー検査
• アレルギー検査
• トキシコロジー検査

第8章 技術別

• 酵素ベースイムノアッセイ
• ラジオイムノアッセイ
• 免疫タンパク質電気泳動法
• 化学発光測定法
• 免疫蛍光測定法
• 免疫比濁法
• その他

第9章 エンドユーザー別

• 病院・診療所
• 診断研究所
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• テストタイプベンチマーキング
• 注目の主要企業リスト

第12章 企業プロファイル

• Abbott Laboratory
  • 企業概要
  • テストタイプテストタイプのポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Thermo Fisher Scientific Inc
• Bio-Rad Laboratories, Inc
• Danaher Corporation
• F. Hoffmann-La Roche Ag
• Enzo Biochem, Inc
• Siemens Aktiengesellschaft
• Ortho Clinical Diagnostics
• Diasorin S.P.A
• Abcam Plc

第13章 免疫タンパク質診断検査の世界市場-DataM

Market Overview

Immunoprotein Diagnostic Testing Market size was valued US$ 11,480.26 million in 2021 and is estimated to reach US$ 20,938.71 million by 2029, growing at a CAGR of 7.9% during the forecast period (2022-2029).

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze certain proteins such as immunoglobulin and pre-albumin. With continuous development in technologies, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Market Dynamics

The global immunoprotein diagnostic testing market is growing owing to the rising prevalence of obesity, rheumatoid arthritis, cancer, type 2 diabetes, infectious diseases, and cardiovascular disease.

Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer is expected to drive market growth.

According to the World Health Organization (WHO), it has been projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths are due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. The number of people in the developing world with diabetes will increase by more than 2.5-fold, from 84 million in 1995 to 228 million in 2025. On a global basis, 60% of the burden of chronic diseases will occur in developing countries. Indeed, cardiovascular diseases are even now more numerous in India and China than in all the economically developed countries in the world put together. As for overweight and obesity, not only has the current prevalence already reached unprecedented levels, but the rate at which it is annually increasing in most developing regions is substantial. The public health implications of this phenomenon are staggering and are already becoming apparent. Hence, the rising prevalence of chronic diseases has raised the demand for rapid diagnosis.

The rising geriatric population coupled with an all-time high incidence of chronic diseases has given an impetus to the global market's growth for immunoprotein diagnostic testing. Moreover, the upswing in demand for immunoprotein diagnostic testing can also be attributed to the prevalence of infectious diseases worldwide. Unhygienic living conditions, especially in underdeveloped regions, have also led to diseases and infections. This has brought the global market for immunoprotein diagnostic testing under the spotlight of attention.

High cost of diagnostic tests is expected to hamper the market growth.

The regulatory framework is very complex and doesn't approve many immunoprotein diagnostic tests easily and high cost of some diagnostic tests can hamper the growth of the market.

Industry Analysis

The global Immunoprotein Diagnostic Testing market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Enzyme based immunoassay segment is expected to hold the largest market share in global immunoprotein diagnostic testing market

Based on technology, the immunoprotein diagnostic testing market is segmented into enzyme-based immunoassay, radioimmunoassay, immunoprotein electrophoresis, chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, and others. Among these, enzyme-based immunoassay (EIA) accounted for the largest market share. EIA has used a diagnostic and quality tool in several laboratories and companies. Also, some of the major companies are developing new products with EIA technology. For instance, Abcam offers Human Complement C3 ELISA Kit for diagnosis.

On the other hand, chemiluminescence assay is expected to grow at the highest growth rate during the forecast period, owing to its features such as high sensitivity and specificity, strong ability to detect antigens in human serum & plasma samples. Chemiluminescence assay is an important tool for the instant diagnosis of several diseases and is ascertained to be more accurate than fluorescence-based detection of labeled probes. On November 6th, 2019, ALPCO has launched its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.

Based on application, the immunoprotein diagnostic testing is be segmented into autoimmune disease testing, infectious disease testing, oncology testing, allergy testing, toxicology testing, and endocrine testing. Among these, oncology testing accounted for the largest market share, with rising demand over the forecast period. The presence of various diagnostic methods, such as Epidermal Growth Factor Receptor (EGFR) testing, helps detect mutations in the EFGR gene, which occurs in patients with non-small cell lung cancer, and this helps in treatment planning. In March 2019, NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, launched the Ventana PD-L1 (SP142) Assay for tumor tissue from patients with a triple-negative subtype of breast cancer. This PD-L1 assay is a companion diagnostic test recently approved by the FDA to identify advanced, metastatic triple-negative breast carcinoma cancer patients who may respond to the immune checkpoint inhibitor therapy TECENTRIQ (atezolizumab) used in combination with chemotherapy. TECENTRIQ is the first immunotherapy approved specifically for breast cancer.

Geographical Analysis

North America region holds the largest market share in the global immunoprotein diagnostic testing market

North America is dominating the global immunoprotein diagnostic testing market accounted for the largest market share, owing to rising incidences of chronic diseases, rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year. By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. They account for 81% of hospital admissions, 91% of all prescriptions filled, and 76% of all physician visit. In another instance, the American Cancer Society projected around 1,806,590 new cancer cases and 606,520 cancer deaths in the United States in the year 2020. Because of such a projection, accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

Competitive Landscape

Some of the major players in the immunoprotein diagnostic testing market include F. Hoffmann-La Roche Ag, Abcam PLC, Abbott Laboratories, Diasorin, Enzo Life Sciences, Randox Laboratories, Siemens, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Ortho Clinical Diagnostics, among others.

The key players are adopting various growth strategies such as expansion, mergers & acquisitions, partnerships, product launches, and collaborations contributing to the Immunoprotein Diagnostic Testing market globally. For instance,

• In July 2019, the U.S. Food and Drug Administration (FDA) cleared for marketing four previously cleared tests with new indications to aid in diagnosing Lyme disease. The tests cleared are the first time that a test has been indicated to follow a new testing paradigm in which two tests called enzyme immunoassays (EIA) are run concurrently or sequentially, rather than the current two-step process in which a separate protein test called a Western Blot must be run after the initial EIA test.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

The Afinion 2: It is an analyser that is a compact, rapid and can perform multi-assay which gives important near patient diagnosis or testing at the point-of-care.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global immunoprotein diagnostic testing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Rising technological advancements and rising prevalence of obesity, rheumatoid arthritis, cancer
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of the device and maintenance
    • 4.1.2.2. Risk of injuries in surgery
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Product Innovations
• 5.6. Unmet Needs

6. By Test Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
  • 6.1.2. Market Attractiveness Index, By Test Type Segment
• 6.2. Immunoglobulin Diagnostic Tests
  • 6.2.1.1. Introduction
  • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. C-Reactive Protein (CRP) Diagnostic Tests
• 6.4. Complement System Proteins Diagnostic Tests
• 6.5. Free Light Chain Diagnostic Tests
• 6.6. Haptoglobin Diagnostic Tests
• 6.7. Prealbumin Diagnostic Tests
• 6.8. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 7.1.2. Market Attractiveness Index, By Application Segment
• 7.2. Autoimmune Disease Testing
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Infectious Disease Testing
• 7.4. Oncology Testing
• 7.5. Allergy Testing
• 7.6. Toxicology Testing

8. By Technology

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
  • 8.1.2. Market Attractiveness Index, By Technology Segment
• 8.2. Enzyme Based Immunoassay
  • 8.2.1.1. Introduction
  • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Radioimmunoassay
• 8.4. Immunoprotein Electrophoresis
• 8.5. Chemiluminescence assay
• 8.6. Immunofluorescence Assay
• 8.7. Immunoturbidity Assay
• 8.8. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 9.1.2. Market Attractiveness Index, By End User Segment
• 9.2. Hospital and clinics
  • 9.2.1.1. Introduction
  • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Diagnostic laboratories
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By S Test Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. Australia
    • 10.5.7.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Test Type Test Types Benchmarking
• 11.4. List of Key Companies to Watch

12. Company Profiles

• 12.1. Abbott Laboratory
  • 12.1.1. Company Overview
  • 12.1.2. Test Type Test Type Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Thermo Fisher Scientific Inc
• 12.3. Bio-Rad Laboratories, Inc
• 12.4. Danaher Corporation
• 12.5. F. Hoffmann-La Roche Ag
• 12.6. Enzo Biochem, Inc
• 12.7. Siemens Aktiengesellschaft
• 12.8. Ortho Clinical Diagnostics
• 12.9. Diasorin S.P.A
• 12.10. Abcam Plc

LIST NOT EXHAUSTIVE

13. Global Immunoprotein Diagnostic Testing Market - DataM

• 13.1. Appendix
• 13.2. About Us and End User
• 13.3. Contact Us